Irvine, CA - Next Pharmaceuticals, Inc. has been issued a patent on Magnolia, a key component in the company's all natural, anti-stress ingredient Relora®. The patented methodology, US 6,582,735, relates to the use of Relora® for weight gain associated with stress and a stress-related condition known as "metabolic syndrome."
According to the Center for Disease Control (CDC), as many as 47 million Americans may suffer from metabolic syndrome, which is characterized by a cluster of conditions including insulin resistance and the presence of obesity, abdominal fat, high blood sugar and triglycerides, high blood cholesterol, and high blood pressure.
"Dietary supplement manufacturers and functional food/beverage companies have a myriad of new product positioning opportunities with the addition of our patented ingredient Relora," says Next Pharmaceuticals President and CEO Bob Garrison. "Our three human studies along with the findings from our current clinical trial with Relora will provide branding opportunities in some hot markets, including weight control."
Next Pharmaceuticals, Inc. is a research and development company that markets its patented or patent-pending ingredients such as Nexrutine to large food, beverage, and dietary supplement companies focused on health enhancement and disease prevention. Relora is distributed exclusively by Wilke Resources, Inc., Lenexa, Kansas (Contact: Jim France, 913-438-5544).